Jonas Oldgren

Summary

Affiliation: Uppsala University Hospital
Country: Sweden

Publications

  1. ncbi request reprint Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation
    Jonas Oldgren
    From Department of Medical Sciences, Cardiology, Uppsala University, Sweden J O, Z H, L W Uppsala Clinical Research Center, Uppsala University, Sweden J O, Z H, J L, A s, L W Duke Clinical Research Institute, Duke Medicine, Durham, NC J H A, C B G, R D L Population Health Research Institute, Hamilton, Canada S J C, J W E, S Y Thomas Jefferson Medical College and the Heart Center, Wynnewood, PA M D E Boston University Medical Center, MA E M H and Department of Medical Sciences, Clinical Chemistry, Uppsala University, Sweden A S
    Circulation 134:1697-1707. 2016
  2. pmc New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis
    Jonas Oldgren
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Eur Heart J 34:1670-80. 2013
  3. doi request reprint Fibrinolytic therapy and bleeding complications: risk predictors from RIKS-HIA
    Jonas Oldgren
    Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
    Heart 96:1451-7. 2010
  4. doi request reprint Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals
    Jonas Oldgren
    Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden
    Am Heart J 155:493.e1-8. 2008
  5. doi request reprint Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial
    Jonas Oldgren
    Uppsala Clinical Research Centre and Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Ann Intern Med 155:660-7, W204. 2011
  6. ncbi request reprint Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment
    Jonas Oldgren
    Uppsala Clinical Research Center, Uppsala University Hospital, S 751 85 Uppsala, Sweden
    Eur Heart J 29:315-23. 2008
  7. ncbi request reprint Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients
    Jonas Oldgren
    Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden
    Eur Heart J 28:699-704. 2007
  8. doi request reprint Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis
    Ziad Hijazi
    From Uppsala Clinical Research Center Z H, J O, U A, A s, L W, Department of Medical Sciences, Cardiology Z H, J O, L W, and Department of Medical Sciences, Clinical Chemistry A S, Uppsala University, Sweden Department of Cardiology, J W Goethe University, Frankfurt, Germany S H H Population Health Research Institute, Hamilton, Ontario, Canada S J C, J W E, S Y Thomas Jefferson Medical College and the Heart Center, Wynnewood, PA M D E and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT P A R
    Circulation 129:961-70. 2014
  9. doi request reprint Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial
    Jonas Oldgren
    Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, S 751 85 Uppsala, Sweden
    Eur Heart J 32:2781-9. 2011
  10. ncbi request reprint Risk prediction in chest pain patients by biochemical markers including estimates of renal function
    Kai M Eggers
    Department of Medical Sciences, Cardiology, University Hospital Uppsala, S 751 85 Uppsala, Sweden
    Int J Cardiol 128:207-13. 2008

Detail Information

Publications37

  1. ncbi request reprint Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation
    Jonas Oldgren
    From Department of Medical Sciences, Cardiology, Uppsala University, Sweden J O, Z H, L W Uppsala Clinical Research Center, Uppsala University, Sweden J O, Z H, J L, A s, L W Duke Clinical Research Institute, Duke Medicine, Durham, NC J H A, C B G, R D L Population Health Research Institute, Hamilton, Canada S J C, J W E, S Y Thomas Jefferson Medical College and the Heart Center, Wynnewood, PA M D E Boston University Medical Center, MA E M H and Department of Medical Sciences, Clinical Chemistry, Uppsala University, Sweden A S
    Circulation 134:1697-1707. 2016
    ....
  2. pmc New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis
    Jonas Oldgren
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Eur Heart J 34:1670-80. 2013
    ....
  3. doi request reprint Fibrinolytic therapy and bleeding complications: risk predictors from RIKS-HIA
    Jonas Oldgren
    Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
    Heart 96:1451-7. 2010
    ..Fibrinolytic treatment for ST-elevation myocardial infarction is associated with increased bleeding risk but is still widely used world wide, mainly because of limited access to primary PCI...
  4. doi request reprint Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals
    Jonas Oldgren
    Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden
    Am Heart J 155:493.e1-8. 2008
    ..We evaluated coagulation activity in relation to gender in patients with acute coronary syndromes and in healthy individuals of similar age, and related coagulation activity to levels of Xa inhibition during dalteparin treatment...
  5. doi request reprint Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial
    Jonas Oldgren
    Uppsala Clinical Research Centre and Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Ann Intern Med 155:660-7, W204. 2011
    ..There are sparse data on the risk for thrombotic and bleeding complications according to the CHADS(2) score in patients receiving anticoagulant therapy...
  6. ncbi request reprint Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment
    Jonas Oldgren
    Uppsala Clinical Research Center, Uppsala University Hospital, S 751 85 Uppsala, Sweden
    Eur Heart J 29:315-23. 2008
    ..We evaluated fondaparinux treatment vs. usual care, i.e. placebo or unfractionated (UF) heparin, in a pre-specified subgroup of 2867 (out of 12 092) patients not receiving reperfusion treatment in the OASIS-6 trial...
  7. ncbi request reprint Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients
    Jonas Oldgren
    Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden
    Eur Heart J 28:699-704. 2007
    ....
  8. doi request reprint Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis
    Ziad Hijazi
    From Uppsala Clinical Research Center Z H, J O, U A, A s, L W, Department of Medical Sciences, Cardiology Z H, J O, L W, and Department of Medical Sciences, Clinical Chemistry A S, Uppsala University, Sweden Department of Cardiology, J W Goethe University, Frankfurt, Germany S H H Population Health Research Institute, Hamilton, Ontario, Canada S J C, J W E, S Y Thomas Jefferson Medical College and the Heart Center, Wynnewood, PA M D E and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT P A R
    Circulation 129:961-70. 2014
    ..This prespecified study investigated these outcomes in relation to renal function...
  9. doi request reprint Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial
    Jonas Oldgren
    Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, S 751 85 Uppsala, Sweden
    Eur Heart J 32:2781-9. 2011
    ..We evaluated the safety and indicators of efficacy of the novel oral direct thrombin inhibitor dabigatran...
  10. ncbi request reprint Risk prediction in chest pain patients by biochemical markers including estimates of renal function
    Kai M Eggers
    Department of Medical Sciences, Cardiology, University Hospital Uppsala, S 751 85 Uppsala, Sweden
    Int J Cardiol 128:207-13. 2008
    ..Early risk stratification of patients with chest pain may be improved by combining cardiac Troponin I (cTnI) results and ECG findings with markers of left-ventricular dysfunction, inflammation or renal function...
  11. doi request reprint Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy
    Ziad Hijazi
    Uppsala Clinical Research Center, Dag Hammarskjolds vag 14B, Uppsala, Sweden
    Circulation 125:1605-16. 2012
    ....
  12. doi request reprint Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
    Lars Wallentin
    Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden
    Lancet 376:975-83. 2010
    ..We aimed to investigate the primary and secondary outcomes of the RE-LY trial in relation to each centre's mean TTR (cTTR) in the warfarin population...
  13. doi request reprint Pathophysiologic mechanisms of persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome
    Kai M Eggers
    Department of Medical Sciences, Cardiology, Uppsala University Hospital, Uppsala, Sweden
    Am Heart J 156:588-94. 2008
    ..We now have studied the associations of persistently elevated cTnI levels to cardiac performance, inflammation, coagulation, coronary status, and treatment strategy in these patients...
  14. doi request reprint Biomarkers in atrial fibrillation: a clinical review
    Ziad Hijazi
    Uppsala Clinical Research Center UCR, Uppsala University, Uppsala Science Park, Uppsala, Sweden
    Eur Heart J 34:1475-80. 2013
    ..This review will highlight novel associations of biomarkers and outcomes in AF as well as recent progress in the use of biomarkers for risk stratification...
  15. ncbi request reprint Risk prediction in patients with chest pain: early assessment by the combination of troponin I results and electrocardiographic findings
    Kai M Eggers
    Department of Cardiology, University Hospital, Uppsala, Sweden
    Coron Artery Dis 16:181-9. 2005
    ..To evaluate the prognostic value of point of care troponin I (TnI) results in combination with findings from the admission electrocardiogram (ECG) in patients with chest pain...
  16. ncbi request reprint Artificial neural network algorithms for early diagnosis of acute myocardial infarction and prediction of infarct size in chest pain patients
    Kai M Eggers
    Department of Medical Sciences, Cardiology, University Hospital Uppsala, S 751 85 Uppsala, Sweden
    Int J Cardiol 114:366-74. 2007
    ..To prospectively validate artificial neural network (ANN)-algorithms for early diagnosis of myocardial infarction (AMI) and prediction of 'major infarct' size in patients with chest pain and without ECG changes diagnostic for AMI...
  17. ncbi request reprint Combining different biochemical markers of myocardial ischemia does not improve risk stratification in chest pain patients compared to troponin I alone
    Kai M Eggers
    Department of Cardiology, University Hospital, Uppsala, Sweden
    Coron Artery Dis 16:315-9. 2005
    ..A multimarker strategy applying results of early measurements of different biochemical markers of cardiac necrosis in combination may improve risk prediction in chest pain patients...
  18. doi request reprint The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
    Ziad Hijazi
    Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden Electronic address
    Lancet 387:2302-11. 2016
    ..We aimed to develop and validate a new biomarker-based risk score to improve the prognostication of major bleeding in patients with atrial fibrillation...
  19. ncbi request reprint An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease
    Stefan K James
    The Research Group of Cardiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Am Heart J 149:619-26. 2005
    ..Inflammation plays an important role in unstable coronary artery disease (CAD). We assessed the kinetics of inflammatory markers from symptom onset in patients with unstable CAD and their relation to myocardial damage...
  20. doi request reprint Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy
    Ziad Hijazi
    Department of Cardiology, Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Heart 100:1193-200. 2014
    ..To evaluate the prognostic importance of transient or persistent elevations of cardiac troponin-I (cTnI) and N-terminal-B-type natriuretic peptide (NT-proBNP) in atrial fibrillation (AF)...
  21. doi request reprint Myeloperoxidase is not useful for the early assessment of patients with chest pain
    Kai M Eggers
    Department of Medical Sciences, Cardiology, Uppsala University Hospital and Uppsala Clinical Research Center, Uppsala, Sweden
    Clin Biochem 43:240-5. 2010
    ..Myeloperoxidase (MPO) has been listed as a potentially useful risk marker in acute coronary syndrome. However, its clinical utility in patients with acute chest pain is not yet defined...
  22. doi request reprint D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy
    Agneta Siegbahn
    Prof Agneta Siegbahn, Department of Medical Sciences, Clinical Chemistry, University Hospital, 751 85 Uppsala, Sweden, Tel 46 18 611 42 51, Fax 46 18 55 25 62, E mail
    Thromb Haemost 115:921-30. 2016
    ..These different effects on the coagulation system might explain the better efficacy and less intracranial bleeding observed with dabigatran compared with warfarin. ..
  23. doi request reprint Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry
    Jonas Oldgren
    Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden J O, L W Population Health Research Institute, Hamilton, Ontario, Canada J S H, C A M, A G, J N, S J C, S Y Jefferson Medical College, Wynnewood, PA, and Cardiovascular Research Foundation, New York, NY M E Department of Medicine, University of Cape Town, Cape Town, South Africa P C Instituto Dante Pazzanesse de Cardiologia, Sao Paulo, Brazil A A St John s Medical College, Bangalore, India P P, A S Cardiovascular Institute and Fuwai Hospital, Beijing, China J Z, L L University Hospital Motol, Prague, Czech Republic P J Eduardo Mondlane University, Maputo, Mozambique A D Boehringer Ingelheim, Ridgefield, CT P A R Semmelweis University, Budapest, Hungary K K Thoraxcenter, University of Groningen, University Medical Center Groningen
    Circulation 129:1568-76. 2014
    ..Atrial fibrillation (AF) is the most common sustained arrhythmia; however, little is known about patients in a primary care setting from high-, middle-, and low-income countries...
  24. pmc The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation
    Ziad Hijazi
    Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden Uppsala Clinical Research Center, Uppsala University, Uppsala Science Park, Uppsala, Sweden
    Eur Heart J 37:1582-90. 2016
    ..Our objective was to develop and validate a new biomarker-based risk score to improve prognostication of stroke in patients with AF...
  25. doi request reprint Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation
    Julia Aulin
    Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Sweden
    Am Heart J 170:1151-60. 2015
    ..Inflammation has been associated with cardiovascular disease and the burden of atrial fibrillation (AF). In this study we evaluate inflammatory biomarkers and future cardiovascular events in AF patients in the RE-LY study...
  26. doi request reprint Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    Lars Wallentin
    Uppsala Clinical Research Center, Uppsala, Sweden
    N Engl J Med 361:1045-57. 2009
    ..Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel...
  27. doi request reprint Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)
    Axel Akerblom
    Department of Cardiology, UppsalaClinical Research Center, Uppsala University, Uppsala, Sweden
    J Am Coll Cardiol 56:470-5. 2010
    ..The aim of this study was to test the noninferiority of eptifibatide relative to abciximab in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI)...
  28. ncbi request reprint Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial
    Christina Christersson
    Department of Cardiology and Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
    Eur Heart J 28:692-8. 2007
    ..e. prothrombin fragment 1 + 2 (F1 + 2) and D-dimer levels. The aim of this substudy was to evaluate the levels of these markers and activated thromboplastin time (APTT) in relation to new ischaemic events or bleeding...
  29. ncbi request reprint Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease
    Jonas Oldgren
    Department of Medical Sciences, Cardiology, Uppsala University Hospital, Uppsala, Sweden
    Thromb Haemost 91:381-7. 2004
    ....
  30. doi request reprint All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome
    Gorav Batra
    Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
    Heart 102:926-33. 2016
    ..To evaluate 90-day cardiovascular outcome in patients after myocardial infarction (MI) in relation to different subtypes of atrial fibrillation (AF) and MI...
  31. doi request reprint Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy
    Niclas Eriksson
    Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Pharmacogenomics 17:1425-39. 2016
    ..We investigated associations between genetic variation in candidate genes and on a genome-wide scale with warfarin maintenance dose, time in therapeutic range (TTR), and risk of major bleeding...
  32. ncbi request reprint Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation
    Ziad Hijazi
    Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
    Clin Chem . 2016
    ..Several strategies have been proposed for prediction of outcomes and individualization of treatments to better balance the benefits of stroke prevention and risks of bleeding during anticoagulation...
  33. doi request reprint Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery
    Ulrica Alström
    Department of Cardiac and Thoracic Anesthesia and Surgery, Uppsala University Hospital, SE 75185 Uppsala, Sweden
    Thromb Res 124:572-7. 2009
    ....
  34. ncbi request reprint Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction
    Kai Marten Eggers
    Department of Cardiology, Cardiothoracic Center, University Hospital, Uppsala, Sweden
    Am Heart J 148:574-81. 2004
    ..Despite improved laboratory assays for cardiac markers and a revised standard for definition of myocardial infarction (AMI), early detection of coronary ischemia in unselected patients with chest pain remains a difficult challenge...
  35. ncbi request reprint [Not Available]
    Andreas Terent
    Uppsala, Sweden Uppsala universitet Institutionen för medicinska vetenskaper Uppsala, Sweden
    Lakartidningen 113:. 2016
    ..The question »early or delayed onset of oral anticoagulant therapy after acute ischemic stroke with atrial fibrillation« needs to be tested in a randomized clinical trial...
  36. doi request reprint The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial
    Ron J G Peters
    Department of Cardiology, Academic Medical Center, Room F3 236, P O Box 22660, 1100 DD Amsterdam, The Netherlands
    Eur Heart J 29:324-31. 2008
    ..In the OASIS-6 trial, fondaparinux significantly reduced mortality and reinfarction without increasing bleeding in 12 092 patients with acute ST elevation MI...
  37. doi request reprint Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) tri
    Marco J D Tangelder
    AstraZeneca R and D, Medical Science, Molndal, Sweden
    Am Heart J 155:382-7. 2008
    ....